ClinicalTrials.gg
CompletedNCT05982314Updated Dec 18, 2024

Extension Safety and Immunogenicity Study of GPNV-001

A Phase 1/2 interventional study of Gamma-PN3 and Pneumovax-23 in Pneumococcal Infections, sponsored by GPN Vaccines. Completed at 1 site in Australia. Open to participants aged 18 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-18.

Sponsored by GPN Vaccines · Phase 1/2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Pneumococcal Infections with a site in Australia — 3 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal Infections · Australia.

Enrollment
14th of 16
60 · median 851
Started
2023
with 2 others
Phase 1/2
Only one
of the 16
Registered
13th of 16
by date
Lead sponsor
3 of 16
GPN Vaccines

Among the 16 studies in Pneumococcal Infections with a site in Australia, this one is the 14th largest by enrollment, is one of 3 that started in 2023, is the only one in phase 1/2, and was the 13th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

3 of the 16 studies in Pneumococcal Infections with a site in Australia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 69 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Pneumococcal Infections with a site in Australia, or all of them as a file.
02

Study summary

A 6 and 12 month safety and immunogenicity study of participants in study GPNV-001, a novel whole-cell pneumococcal vaccine.

Read the detailed description

A 6 and 12 month safety and immunogenicity study of participants in study GPNV-001, a novel whole-cell pneumococcal vaccine. Up to 20 participants per cohort will be invited.

03

Conditions studied

  • Pneumococcal Infections
04

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Completion of study GPNV-001 as per protocol with no significant deviations.
  2. Has provided written .

Exclusion criteria

Exclusion Criteria:

  1. Potential participants will be excluded if they have received a pneumococcal vaccine since the end of study visit for study GPNV-001
  2. A potential participant has had an episode of pneumonia since completing Study GPNV-001
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Gamma-PN3 50 mcg

    In GPNV-001 participants will have received 2 doses of 50 mcg Gamma-PN3 at intervals of 4 weeks

    Biological: Gamma-PN3

  • Experimental
    Gamma-PN3 250 mcg

    In GPNV-001 participants will have received 2 doses of 250 mcg Gamma-PN3 at intervals of 4 weeks

    Biological: Gamma-PN3

  • Experimental
    Gamma-PN3 1000 mcg

    In GPNV-001 participants will have received 2 doses of 1000 mcg Gamma-PN3 at intervals of 4 weeks

    Biological: Gamma-PN3

  • Active comparator
    Pneumovax 23

    In GPNV-001 participants will have received one 0.5ml dose of Pneumovax-23 followed by saline placebo 4 weeks later

    Biological: Pneumovax-23

  • Active comparator
    Prevenar-13

    In GPNV-001 participants will have received one 0.5ml dose of Prevenar-13 followed by saline placebo 4 weeks later

    Biological: Prevenar-13

  • Placebo comparator
    Placebo

    In GPNV-001 participants will have received two doses of 0.5 ml saline placebo at intervals of 4 weeks.

    Biological: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Serum IgG titre to Gamma-PN3

    Serum IgG titre to the vaccine

    Time frame: 6 months and 12 months

  2. Serious adverse events

    Serious adverse events occurring after day 57 of study GPNV-001

    Time frame: 6 months and 12 months

Secondary outcomes

  1. Opsonophagocytic antibodies to pneumococcal strains

    Serum OPA titres to up to 24 pneumococcal serotypes

    Time frame: 6 months and 12 months

07

Study locations

1 site
  • University of Adelaide
    Adelaide, South Australia 5005, Australia
08

References and documents

Individual participant data

Plan to share: No — No plan as yet

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Aug 2024, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2023
First posted
Aug 8, 2023
StartActual
Jul 17, 2023
Primary completionActual
Aug 30, 2024
CompletionActual
Aug 30, 2024
Last update
Dec 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05982314
Lead sponsor
GPN Vaccines
Responsible party
Sponsor
First posted
Aug 8, 2023
Start date
Jul 17, 2023
Primary completion
Aug 30, 2024
Completion
Aug 30, 2024
Last update
Dec 18, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion